CORRECTING and Replacing – GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients
August 13, 2021
Potential to provide approximately $15 million a year in savings for life-enhancing medications
SANTA MONICA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — In a release issued earlier today by GoodRx, Inc. (Nasdaq: GDRX), please note the announcement has been revised to include information about Synjardy, Synjardy XR and Stiolto Respimat.
Read the source article at Aktien
2021-08-09 15:16:00
